LFST

In November and December 2025, BMO Capital and Barclays initiated "Outperform" and "Overweight" ratings, respectively. In February 2026, Keybanc, UBS, and Canaccord Genuity reiterated or maintained positive ratings, with UBS raising its price target to $12.00. On May 7, 2026, LifeStance reported strong first-quarter results, exceeding expectations and raising full-year guidance, causing the stock to surge. However, on May 8, 2026, the stock declined following the announcement of a secondary public offering. In late April 2026, LifeStance Health was added to the S&P SmallCap 600 and S&P Composite 1500 indices. Insider selling has also been noted.